middle.news
CLINUVEL Secures EMA Scientific Advice for Pivotal Vitiligo Phase III Study
9:18am on Friday 24th of April, 2026 AEST
•
Healthcare
Read Story
CLINUVEL Secures EMA Scientific Advice for Pivotal Vitiligo Phase III Study
9:18am on Friday 24th of April, 2026 AEST
Key Points
EMA endorses 'totality of evidence' for SCENESSE vitiligo trial
Phase III CUV107 study to enrol 300 patients starting second half 2026
Primary endpoint focuses on 50% repigmentation excluding hands and feet
Patient-reported outcomes and photographic review integral to evaluation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clinuvel Pharmaceuticals (ASX:CUV)
OPEN ARTICLE